Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16485964 | 0.81 | HTT (0.43) | MEN1KMT2ACYP1A2SMN1; SMN2GAA | |
| SCHEMBL23247712 | 0.78 | MEN1 (0.43) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL19410750 | 0.77 | OPRM1 (0.43) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL28040760 | 0.76 | ALDH1A1 (0.43) | MEN1KMT2ALMNACYP1A2KDM4E | |
| SCHEMBL15650377 | 0.76 | MEN1 (0.41) | MEN1KMT2ALMNACYP1A2CYP3A4 | |
| SCHEMBL23563098 | 0.76 | OPRM1 (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10371110 | 0.75 | MAPT (0.35) | MEN1KMT2AKDM4ESMN1; SMN2GAA | |
| SCHEMBL6737967 | 0.75 | OPRM1 (0.61) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL23541122 | 0.75 | OPRM1 (0.41) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL2924521 | 0.74 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809575-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-2909195-B1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| EP-2776416-B1 | PHARMACEUTICAL COMPOUNDS | RE VIRAL LTD (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20150259367-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150259367-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (US) | 2015-09-17 | — | — | US | disclosed |
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | re: Viral Ltd (GB) | 2014-10-16 | — | — | US | disclosed |
| EP-2776416-A1 | PHARMACEUTICAL COMPOUNDS | Re:Viral Ltd. (GB) | 2014-09-17 | — | — | EP | disclosed |
| WO-2014060411-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2013068769-A1 | PHARMACEUTICAL COMPOUNDS | RE:VIRAL LTD (GB) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | CYP2S1, H1-2, CBR1 | MEN1 2582/4885KMT2A 2473/4885LMNA 1620/4885 |
| US-20150259367-A1 | RSV ANTIVIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, RTF1 | MEN1 4051/4885KMT2A 1871/4885LMNA 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.